HollisterStier Signs Development Agreement

HollisterStier signed a contract with Roxro Pharma, Inc. to fill/finish Roxro’s first pain management candidate, ROX-888, through commercialization, under cGMP. The two companies are purchasing new and specialized equipment to accommodate the project. Roxro plans to file an NDA for ROX-888 with the FDA after completion of its Phase III trials.

“Our custom multidisciplinary team is excited to assist Roxro in further developing their unique drug product and delivery system,” stated Anthony Bonanzino, Ph.D., HollisterStier’s president and chief executive officer. “This is further evidence of our commitment to providing excellent customer service and fulfilling specific contract manufacturing goals for each of our clients.”